Matthew Hammond, MD
Ophthalmology · Mesa, AZNPI 1902829799
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Carl Zeiss Meditec, Inc. at 24.4% of the total. That places this record below the midpoint for ophthalmology clinicians in AZ, where the typical reported total is $1,526.
Across 58 payments — averaging $24.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$347
- Tarsus Pharmaceuticals, Inc.$230
- Rxsight Inc$107
- Alcon$106
- AbbVie$89
- Amgen$79
- plus $462 from 17 others
Across 14 payments — averaging $14,028 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$119K
- Oyster Point Pharma, Inc.$59K
- Alcon Research LLC$18K
What the payments were for
- Speaking & faculty fees$262%
- Food & beverage$1,34395%
- Education$151%
- Gifts$363%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 5 | $347 |
| Tarsus Pharmaceuticals, Inc. | 7 | $230 |
| Rxsight Inc | 5 | $107 |
| Alcon | 6 | $106 |
| AbbVie(2 entities) | 5 | $89 |
| Amgen | 5 | $79 |
| Carl Zeiss Meditec USA, Inc. | 2 | $74 |
| Sun Pharmaceutical Industries Inc. | 3 | $57 |
| Sight Sciences, Inc. | 3 | $48 |
| Glaukos Corporation | 1 | $38 |
| Katena Products, Inc. (dba Corza Medical) | 2 | $36 |
| Ocular Therapeutix, Inc. | 2 | $32 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $27 |
| Leadiant Biosciences, Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $17 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
| Visioneering Technologies, Inc. | 1 | $16 |
| Quidel Corporation | 1 | $15 |
| Akorn Operating Company LLC | 1 | $15 |
| Biotissue Holdings Inc. | 1 | $15 |
| Iridex Corporation | 1 | $15 |
| Dutch Ophthalmic, USA | 1 | $15 |
| Lensar, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARTEVO 800$149
- IOLMaster 700$149
- VisuMax$149
- QUATERA 700$139
How this compares
$1,419 in reported general payments places this provider in the 45th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 15 | $27,642 |
| RestasisCyclosporine | 24 | $17,989 |
| Prednisolone Acetate | 155 | $6,121 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 43 | $3,145 |
| MoxifloxacinMoxifloxacin Hcl | 65 | $1,563 |
| Ketorolac Tromethamine | 64 | $1,488 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 68 | $849 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $794 |
| Brimonidine Tartrate | 14 | $788 |
| Latanoprost | 106 | $703 |
| Timolol Maleate | 32 | $254 |
| Cyclopentolate Hcl | 11 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $230 | $27,64215 claims |
| AbbVieRestasis | $89 | $17,98924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Mesa
- Warren HillMesa$1.1M
- Derek KunimotoMesa$138K
- Yuri McKeeMesa$100K
- Mark BarakatScottsdale$794K
- Anne ZakiSun City West$518K
- Pravin DugelPhoenix$176K
- Shamil PatelGlendale$116K
- Nishi ShahPhoenix$92K
- Lisa MihoraPeoria$91K
- George ReissGlendale$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.